Dry Eye

Cynthia Matossian, MD, FACS, discusses the short- and long-term treatment options for dry eye flares.

Eric Donnenfeld, MD, highlights study results exhibiting risuteganib as a potential treatment option for dry eye disease.

Dr Matossian explains the importance of treating dry eye flares and what can happen if they are left unchecked.

Dr Matossian elaborates on how both patients’ and physicians’ awareness of dry eyes flares affects their eyesight and how they move forward with treatment.

Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.

Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).

The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.

EyeGate Pharmaceuticals, Inc.'s lead product candidate is designed to treat dry eye disease-induced ocular surface inflammation.

Researchers seek to identify new serological biomarkers that could better characterize Sjogren’s syndrome and overcome the limitations of traditional antibodies.

Unique clinical trials and novel products of interest currently under investigation for the treatment of dry eye disease.

A panel of ophthalmologists and optometrists conclude a discussion about dry eye disease by commenting on advances occurring in the field and future expectations for managing patients.

Strategies that can help eye care specialists work with patients to establish and stick to treatment plans for dry eye disease.

Types of in-office procedures currently being used by ophthalmologists and optometrists to aid in the treatment of dry eye disease.

Eye care specialists describe when corticosteroid therapy should be considered to treat dry eye disease and describe best practices when treating pre-surgical patients.

The most common types of artificial tears recommended to help manage dry eye disease and the importance of proper use for full benefit.

Eye care professionals discuss their comfort in recommending oral omega-3 fatty acids to help treat dry eye disease.

Increased time on digital devices and erratic schedules have disrupted patients’ management of their MGD and dry eye disease.

How to select and discuss sequential therapy with patients who have dry eye disease and set expectations for treatment.

Resources and strategies that can be used to help educate patients about dry eye disease and optimize adherence to therapy.

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

Criteria that would prompt further evaluation for dry eye disease and the types of tests used to work-up and accurately diagnose the condition.

Eye care professionals explain the impact of unstable tear film and untreated dry eye disease on patient quality of life.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Christopher Starr, MD, discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

The impact of autoimmune and systemic diseases as well as environmental triggers on the development of dry eye disease.